塞来昔布对胃肠毒副反应及用于肿瘤靶向防治的可行性研究  

Gastrointestinal adverse effects of celecoxib and its feasibility of application in target therapy on neoplasm

作　　者：郑伟华[1] 卢奕云[2] 何蕙泾[1] 

机构地区：[1]广东省人民医院肿瘤内科,广东广州510080 [2]广东省人民医院儿科,广东广州510080

出　　处：《肿瘤防治杂志》2004年第9期975-976,共2页China Journal of Cancer Prevention and Treatment

基　　金：广东省科技厅科技攻关计划资助项目(B3 0 3 0 10 12 )

摘　　要：为了研究在化疗期间塞来昔布的胃肠道毒副反应及用于恶性肿瘤靶向预防及治疗的可行性 ,分别采用塞来昔布及双氯芬酸钠对 46例轻中度疼痛的晚期癌症患者进行跟踪治疗 ,并从胃肠道毒副反应、耐受性及安全性等方面加以分析比较。临床结果显示 ,塞来昔布与双氯芬酸钠在抗肿瘤疼痛方面疗效大致相同 ,塞来昔布引起的一过性胃肠不适为 19 4% ,未见症状性溃疡。初步研究结果提示 ,可以充分利用塞来昔布特异性的COX 2抑制特性 ,有效地抑制转移性肿瘤引起的轻中度疼痛 ,它对上消化道毒副反应小、安全性好的优点和潜在的抑制肿瘤发生及发展的作用 ,可以进一步用于恶性肿瘤的靶向预防及治疗。To investigate the feasibility of using celecoxib in target therapy on neoplasm and its gastrointestinal adverse effects,we used the randomized controlled trial (RCT) method to investigate painkilling scenarios for 46 cancer patients with mild to moderate pain, and compared the results in terms of side effects, tolerance and safety between two classified groups: the experiment group, using celecoxib capsules, and the reference group, using diclofenac sodium sustained release tablets. The results have demonstrated that the effective rate of restraining pain in the two groups was similar; the occurrence of episode gastrointestinal discomfort was 19.4%, and no ulcer with symptoms was caused in the experiment group. The preliminary research has demonstrated the advantages of using the special COX-2 inhibiter, found in celecoxib, of being able to effectively restrain the mild to moderate pain caused by metastatic tumor, while having little adverse effects on upper gastrointestinal tract and providing the patient with good safety. With these advantages and the potential to restrain the production and development of cancers, it can be of further usage in the target prevention and treatment of cancers.

关 键 词：肿瘤/药物疗法 疼痛/药物疗法 消炎药 非甾类 

分 类 号：R730.53[医药卫生—肿瘤]